Virtual Library
Start Your Search
T. Hisada
Author of
-
+
P2.01 - Advanced NSCLC (ID 618)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Advanced NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 10/17/2017, 09:00 - 16:00, Exhibit Hall (Hall B + C)
-
+
P2.01-027 - Clinical Significance of Topoisomerase-II Expression in Patients with Non-Small Cell Lung Cancer Treated with Amrubicin (ID 8859)
09:00 - 09:00 | Author(s): T. Hisada
- Abstract
Background:
Amrubicin (AMR) is one of treatment options in patients with previously treated advanced non-small cell lung cancer (NSCLC). Although topoisomerase-I (Topo-I) and topoisomerase-II (Topo-II) are identified as a targeting molecular of AMR, it remains unclear about the relationship between the efficacy of AMR and the expression level of these markers.
Method:
Between April 2004 and May 2014, 56 patients with advanced NSCLC who had received AMR were retrospectively analyzed. Clinical data including histological type, response to treatment, and survival were collected from medical records. The expression level of Topo II within tumor cell were evaluated by immunohistochemical staining.
Result:
The majority of enrolled patients were men (66.1%) and median age was 69 years (range, 43-78 years). The tumor samples consist of adenocarcinoma (69.6%), squamous cell carcinoma (21.4%), poorly differentiated carcinoma (3.6%), pleomorphic carcinoma (1.8%) and unclassified NSCLC (3.6%) Twenty percent of tumors had EGFR mutations. Percentages of tumors overexpressing Topo-I and Topo-II were 57% and 30%, respectively. Median progression-free survival (PFS) and overall survival (OS) for all patients was 2.4 and 10.9 months, respectively. Patients with low Topo-II expression had significantly longer OS than those with high Topo-II expression (12.9 months vs. 7.0 months, p<0.05) whereas there was no significant association between Topo-II expression status and PFS. The number of AMR treatment cycles, poor performance status, advanced stage and elevated Topo-II expression were significantly associated with unfavorable OS (P<0.05). Meanwhile, Topo-I expression status was not significantly associated with PFS or OS in the patients with NSCLC.
Conclusion:
The present study suggests that the expression levels of Topo-II (but not Topo-I) are associated with in patients with NSCLC receiving AMR.
-
+
P2.15 - SCLC/Neuroendocrine Tumors (ID 716)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: SCLC/Neuroendocrine Tumors
- Presentations: 2
- Moderators:
- Coordinates: 10/17/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P2.15-005 - Post-Progression Survival Is Strongly Linked to Overall Survival in Refractory Small-Cell Lung Cancer Patients Who Received Amrubicin (ID 8845)
09:30 - 09:30 | Author(s): T. Hisada
- Abstract
Background:
The benefits of second-line chemotherapy on the overall survival (OS) of small-cell lung cancer (SCLC) patients might be confounded by subsequent therapies. In this study, we aimed to determine the influence of progression-free survival (PFS) and of post-progression survival (PPS) on OS after second-line chemotherapy in patients with refractory SCLC treated with amrubicin monotherapy.
Method:
We analyzed the data of 35 patients with refractory SCLC who were treated with amrubicin monotherapy as second-line chemotherapy between July 2005 and December 2015. The correlations of PFS and PPS with OS were statistically analyzed at the individual level using Spearman rank correlation and linear regression analyses.
Result:
The correlation between PPS and OS was strong (r = 0.88, p < 0.05, R[2 ]= 0.87), while that between PFS and OS was weak (r = 0.60, p < 0.05, R[2] = 0.15). The number of regimens administered after disease progression post-second-line chemotherapy was significantly associated with PPS (p = 0.003).
Conclusion:
OS is more strongly linked to PPS than to PFS in refractory SCLC patients who undergo amrubicin monotherapy as a second-line treatment. Moreover, receiving additional regimens after second-line treatment is a significant independent prognostic factor for PPS. Taken together, our results indicate that additional treatments administered after second-line chemotherapy favorably affect the OS of refractory SCLC patients treated with amrubicin monotherapy.
-
+
P2.15-016 - Clinical Significance of Topoisomerase-II Expression in Patients with Relapsed HGNEC of the Lung Treated with Amrubicin (ID 9331)
09:30 - 09:30 | Author(s): T. Hisada
- Abstract
Background:
Amrubicin (AMR) monotherapy is one of treatment options in patients with relapsed high grade neuroendocrine carcinoma (HGNEC) of the lung. Although topoisomerase-II (Topo-II), a target of AMR, has been reported to be a predictive or prognostic marker for chemosensitivity and clinical outcomes in various types of malignancies, its role remains unknown in this population.
Method:
Eighty-four patients with relapsed HGNEC (consisting of small cell lung cancer [SCLC] and large cell neuroendocrine carcinoma [LCNEC]) who received AMR monotherapy between 2003 and 2015 were enrolled into this study. We retrospectively collected clinical data including histological type, anti-tumor effect, and survival data from medical records. The expression levels of Topo-II were examined by immunohistochemical staining in tumor specimens obtained from surgical resection or biopsy.
Result:
The majority of enrolled patients were men (89%) and had a histological type of SCLC (92%) with a median age of 70 years (range, 49-83 years). Twenty-three percent of patients had poor performance status of 2 to 4. Sixteen percent of patients exhibited Topo-II overexpression in the tumors. The overall response rates in patients with high and low expression of Topo-II were 38.5% and 25.7%, respectively (p = 0.34). In multivariate analysis, patients with high expression of Topo-II had significantly longer progression-free survival (Hazard Ratio [HR] 0.39, p < 0.01) and overall survival (HR 0.48, p = 0.04).
Conclusion:
Our findings suggest that Topo-II expression is associated with clinical outcomes in patients with relapsed HGNEC receiving AMR monotherapy.
